Vimarsana
Biggest News Aggregation in the World

Page 47 - Exact Science News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Exact Science. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Exact Science Today - Breaking & Trending Today

Exact Sciences (EXAS) Q1 2021 Earnings Call Transcript - Vimarsana News

Exact Sciences (EXAS) Q1 2021 Earnings Call Transcript

Operator Ladies and gentlemen, thank you for standing by, and welcome to the Exact Sciences' first-quarter 2021 earnings call. [Operator instructions] I would now like to hand the conference over to your speaker today, Mr. Erik Holznecht, senior financial analyst. Sir, please begin. Erik Holznecht -- Senior Investor Relations Associate Thank you, Brent. And thanks to all of you for joining us for Exact Sciences' first-quarter 2021 conference call. On the call today are Kevin Conroy, the company's chairman and CEO; and Jeff Elliott, our chief financial and chief operating officer. Exact Scien...

Source: fool.com
Cologuard® CRC Screening Test Most Cost-Effective Test in Medically Underserved Alaska Native People - Vimarsana News

Cologuard® CRC Screening Test Most Cost-Effective Test in Medically Underserved Alaska Native People

Mayo Clinic Proceedings showing that Cologuard (mt-sDNA) is the most cost-effective colorectal cancer (CRC) screening option in the Alaska Native population, as compared to colonoscopy and the fecal immunochemical test (FIT), for a wide range of adherence scenarios. According to the model, Cologuard produced the highest number of quality adjusted life years (QALYs) gained and the largest reduction in CRC incidence. 1 Colorectal cancer is the second leading cause of cancer death for men and women in the United States, 2 in part because many cancers go undetected until later stages when treatm...

Medtech companies look to post-pandemic home testing beyond COVID-19 - Vimarsana News

Medtech companies look to post-pandemic home testing beyond COVID-19

First published on Encouraged by the development of rapid at-home coronavirus tests, medtech companies are now betting on the potential to sell over-the-counter and direct-to-consumer diagnostics for diseases beyond COVID-19. The pandemic has enabled consumers to get tested for the virus in the privacy of their homes, a convenience that companies like Abbott Laboratories and Quest Diagnostics are hoping will appeal to people when it comes to other diagnostics. Home testing was already rising worldwide, as consumers take a more proactive role in their healthcare. COVID-19 is likely speeding t...

2 Cathie Wood Picks That Can Become Bigger Winners Than Tesla - Vimarsana News

2 Cathie Wood Picks That Can Become Bigger Winners Than Tesla

ARK Fintech Innovation ETF and the ARK Next Generation Internet ETF. The digital payment company's share price soared in 2020 after the coronavirus pandemic forced people to rapidly transition from an in-person to an online way of life. Although the stock fell almost 30% from its all-time high during the February tech sell-off, it now seems to be on a path of recovery. The digital payments market was estimated to be worth $58.3 billion in 2020 and is expected to grow at a compound annual growth rate (CAGR) of 19.4% from 2021 to 2028. Considering the huge opportunity unfolding, PayPal's offer...

Source: fool.com
Madison-based Exact Sciences broadens scope in cancer diagnostics - Vimarsana News

Madison-based Exact Sciences broadens scope in cancer diagnostics

SHELLEY K. MESCH When Exact Sciences moved to Madison from Boston in 2009, the company had 20 employees and the intention of developing a colon cancer screening test. Now, millions of people are screened each year using Exact Sciences’ Cologuard, the company employs more than 5,000 people, and multiple tests are in development for various types and aspects of cancer. In the last three years, Exact Sciences has broadened its diagnostic abilities by acquiring several companies and purchasing the exclusive use of a testing technology that can detect cancer. The acquired products...